Mark Lackner is a notable inventor based in South San Francisco, CA (US). He has made significant contributions to the field of cancer treatment, holding a total of 4 patents. His work focuses on innovative methods for assessing cancer responsiveness and drug resistance.

Latest Patents

One of Lackner's latest patents is titled "Use of human epididymis protein 4 (HE4) for assessing responsiveness of MUC 16-positive cancer treatment." This invention relates to methods and kits that assess the responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. The methods include measuring HE4 levels in a sample from a subject and comparing it with previous samples. Additionally, it may involve administering a therapeutically effective amount of a MUC16 antagonist. Another significant patent is "Genetic variations associated with drug resistance," which provides methods to determine if a cancer is resistant to anti-mitotic agents, including T-DM1. This involves assessing the amplification and/or overexpression of the ABCC3 gene in the cancer.

Career Highlights

Mark Lackner has worked with prominent companies in the pharmaceutical industry, including Genentech, Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has contributed to his expertise in cancer research and treatment.

Collaborations

Throughout his career, Lackner has collaborated with notable colleagues such as Lukas C. Amler and Guy L. Cavet. These partnerships have likely enhanced his research and innovation in the field.

Conclusion

Mark Lackner's contributions to cancer treatment through his patents and collaborations highlight his role as an influential inventor. His work continues to impact the medical community and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.